Prime Minister David Cameron announced a top-level review of UK policy yesterday, hoping to develop new business models for antibacterial development and use (UK Gov’t announcement here; reactions here by the FT (gated) and The Guardian). Jim O’Neill (an economist!!), will lead the panel.
The BBC asked for my views:
In the US, we released the ASPE report on antibiotic incentives last month (TIE discussion here), and the PCAST antibiotics report to President Obama should arrive next week. Many reports; fewer substantial actions. But I am encouraged by the high-level attention by the President and Prime Minister.